Hiv Infection

Long-acting injectable cabotegravir/rilpivirine paired with extensive support services for nonsuppressed people with HIV with adherence barriers would likely increase viral suppression and improve survival, researchers found.

Early combination ART initiation during primary HIV infection can lead to sustained virological suppression after switching to dolutegravir monotherapy, data from the EARLY-SIMPLIFIED study suggests.

The FDA has released new recommendations to measure blood donor eligibility that will eliminate time-based deferrals and screening questions targeting men who have sex with men and the women who have sex with them.

During the early rollout of dolutegravir in South Africa, women were less likely to receive the new treatment than men, despite dolutegravir being associated with improved outcomes, researchers found.

The FDA has proposed a change to its blood donation policy from time-based deferrals for men who have sex with men to “gender-inclusive, individual risk-based” assessments to protect the blood supply from HIV, the agency announced Friday.

The introduction of long-acting injectable cabotegravir PrEP in sub-Saharan Africa could result in fewer future AIDS deaths and new infections, while being a cost-effective alternative to oral PrEP, according to a recent study.

There was plenty of FDA news this year not related to COVID-19.